Roche’s top seller faces rival four years after patent expiry
Antibody-drug conjugate with FDA gets six-month review.
Body unconvinced by clinical data for Venclyxto .
Investment fund kick-starts phase 2 trial in CMML
Imbruvica approved in marginal zone lymphoma.
Sales of Humira could peak above $18 billion – CEO
California’s Kite strikes deals with Fosun and Daiichi Sankyo.
Pharma M&A could surge in 2017, says report
FDA concerned over potential liver toxicity.